Following the full data release from Johnson & Johnson (JNJ)/Protagonist Therapeutics’ (PTGX) FRONTIER 1 study of JNJ-2113 on July 4th, Oppenheimer continues to view the results as positive, but less impressive than seen for best-in-class monoclonals in this indication. The results appear superior to current data for the TYK2s at the top dose and schedule. However, the firm notes that this includes an additional month of dosing for JNJ-2113 vs. the schedule evaluated in the TAK-279 study. Oppenheimer remains bullish on Ventyx Biosciences (VTYX), and sees VTX958 as having the potential to improve on both TAK279 and JNJ-2113 results. The firm reiterates an Outperform rating on Ventyx’s shares with a price target of $62.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTYX:
- Wells Fargo expects Ventyx Biosciences’ shares to work into 2H23 catalysts
- Ventyx Biosciences management to meet virtually with Piper Sandler
- Ventyx Biosciences initiates dosing in Phase 1 trial of VTX3232
- Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
- Ventyx Biosciences assumed with an Outperform at Credit Suisse